US Oncology Affiliated Physicians to Present and Receive Honors at ASCO

Oral Abstracts:

Joyce O'Shaughnessy, MD, Texas Oncology - Baylor Sammons Cancer Center:

Tuesday, June 08,  9:30AM – 12:30 PM (10:45 AM)  E Hall D1

• A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC)

Joanne Blum, MD, PhD, Texas Oncology - Baylor Sammons Cancer Center

Tuesday, June 08,  9:30 AM – 12:30 PM (9:30 AM) E Hall D1

• A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane.

Jeff Sharman, MD, Willamette Valley Cancer Institute and Research Center;

Kathryn Kolibaba, MD, Northwest Cancer Specialists - Vancouver Cancer Center

Thomas Boyd, MD, North Star Lodge Cancer Center, Yakima, Wash.

Saturday, June 05,   1:00 – 4:00 PM (3:45 PM)    E354a

• Effect of BTK inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study

William R. Berry, MD, Cancer Centers of North Carolina - Raleigh

Sunday, June 06,     9:30 AM – 12:30 PM  (11:15 AM)   E Hall D2

• Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial.

Late Breaking Oral Presentation:

Michael G. Teneriello, MD, Texas Oncology - Austin Central  

Sunday, June 06,   9:30 AM – 12:30 PM (11:45 AM)   E Arie Crown Theater

• Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Final safety and efficacy report.

Clinical Science Symposium:

Daniel D. Von Hoff, MD, FACP, US Oncology Research and Translational Genomics Research Institute (TGen)

Sunday, June 06,   8:00 AM – 9:30 AM (8:45 AM)    E345a

• Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors.

Donald A. Richards, MD, PhD, Texas Oncology – Tyler

Monday, June 07,  9:45 AM – 11:15 AM (10:15 AM) E Arie Crown Theater

• Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study.

Poster Discussions:

Michael G. Teneriello, MD, Texas Oncology - Austin Central  

Poster #5  Sunday , June 06,    2:00 PM – 6:00 PM  E450a

Discussion  5:00 PM – 6:00 PM   E Arie Crown Theater

• PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer  Poster discussion

Mark Fleming, MD, Virginia Oncology Associates - Hampton

Michael Kolodziej, MD, New York Oncology Hematology - Albany Medical Center

Sanjay Awasthi, MD, Texas Oncology - Arlington South

Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer Center

Danko Martincic, MD, Cancer Care Northwest – Spokane Valley

Guru Sonpavde, MD, Texas Oncology - Deke Slayton Cancer Center

Yunfei Wang; Kristi A. Boehm; Lina Asmar, PhD: US Oncology Research

Poster #12  Monday, June 07,    8:00 AM – 12:00 PM   450a

Discussion 12 – 1 PM    E Hall D2

• Results of a randomized phase II study of mitoxantrone vs mitoxantrone with cetuximab in metastatic castrate resistant prostate cancer previously treated with docetaxel-based chemotherapy.  Poster discussion

Donald A. Richards, MD, PhD, Texas Oncology – Tyler

Joe Stephenson, MD, Cancer Centers of The Carolinas

Lawrence E. Garbo, MD, New York Oncology Hematology - Albany Medical Center

Poster #23  Friday, June 04,  2:00PM - 6:00PM E 450b

Discussion   5:00 – 6:00 PM       E354a

• A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC).

Donald A. Richards, MD, PhD, Texas Oncology - Tyler

Poster #22  Tuesday, June 08, 8:00 AM - 12:00 PM    S403

Discussion   11:00 AM – 12:00 PM     S406 (Vista room)

• Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).

Donald A. Richards, MD, PhD, Texas Oncology - Tyler

Lawrence E. Garbo, MD, New York Oncology Hematology

Joe Stephenson, MD, Cancer Centers of The Carolinas

Poster #23  Friday, June 04,    2:00 PM - 6:00 PM     E450b

Discussion     5:00 PM – 6:00 PM    E354a

• A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC).

Robert N. Raju, MD, Dayton Oncology & Hematology – Kettering

Poster #15  Saturday, June 05,   8:00 AM - 12:00 PM E450a

Discussion      12:00 PM – 1:00 PM     E354a

• A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors.

Michael G. Teneriello, MD, Texas Oncology - Austin Central

Poster #5  Sunday, June 06,   2:00 PM – 6:00 PM E450a

Discussion   5:00 PM – 6:00 PM    E Arie Crown Theater

• PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer

Patrick J. Flynn, MD, Minnesota Oncology - Minneapolis

Poster #1  Tuesday, June 08,   8:00 AM – 12:00 PM E450a

Discussion    11:00 AM – 12:00 PM   E353

• Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5.

Patrick J. Flynn, MD, Minnesota Oncology - Minneapolis

Poster #10  Saturday, June 05,    8:00 AM - 12:00 PM     S103

Discussion   12:00 PM – 1:00 PM     S100b

• NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM

General Posters:

Matthew Galsky, MD, Comprehensive Cancer Centers of Nevada - Twain

Guru Sonpavde, MD, Texas Oncology - Deke Slayton Cancer Center

Beth Hellerstedt, MD, Texas Oncology - Austin Central

Scott McKenney, MD, Texas Oncology - Mamie McFadden Ward Cancer Center Beaumont

Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer Center

Mary A. Rauch; Yunfei Wang; Kristi A. Boehm; Lina Asmar, PhD: US Oncology Research

Poster #1H  Monday, June 07,  1:00 PM – 5:00 PM    S Hall A2

• Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma.  

David McCollum, MD, Texas Oncology - Baylor Sammons Cancer Center

Darren M. Kocs, MD, Texas Oncology - Round Rock

Punit Chadha, MD, Texas Oncology - South Austin

Donald A. Richards, MD, PhD, Texas Oncology – Tyler

Yunfei Wang; Kristi A. Boehm; Lina Asmar, PhD: US Oncology Research

Poster #14D  Sunday, June 06,  2:00 PM - 6:00 PM      S Hall A2

• A randomized Phase II trial of preoperative chemoradiotherapy with or without cetuximab in locally-advanced adenocarcinoma of the rectum.

Thomas H. Cartwright, MD, Ocala Oncology Center

Matthew Clayton; Jody Garey, PharmD; Kristi A. Boehm, US Oncology Research on behalf of US Oncology Pathways Task Force

Poster #13C  Sunday, June 06,  2:00 PM - 6:00 PM  S Hall A2

• Use of an Electronic Health Record (iKnowMed), in conjunction with evidence-based pathways, permits more complete data capture for outcome measurement in colorectal cancer patients treated with 1st-line therapy in the US Oncology network.

Marcus A. Neubauer, MD, Kansas City Cancer Center - Southwest

Debra A. Patt, MD, Texas Oncology - Austin Central

Janet L. Espirito, PharmD; Matthew Clayton; US Oncology Pathways Task Force

Poster #27G  Monday, June 07,   1:00 PM – 5:00 PM    S Hall A2

• Combination vs. sequential chemotherapy for metastatic breast cancer: An evaluation of outcomes from a community oncology network.

Susan N. Hoang, PharmD; Innovent Oncology

J. Russell Hoverman, MD, Texas Oncology

Brian Turnwald; US Oncology Pathways Task Force

Poster #34A  Monday, June 07,      1:00 PM – 5:00 PM      S Hall A2

• 2nd line pancreatic cancer therapy: Patterns of care and survival.

Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer Center

Poster #7A  Monday, June 07,   1:00 PM – 5:00 PM    S Hall A2

• Long-term sorafenib safety profile in > 700 patients with renal cell carcinoma treated for 12 to 42 months.

Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer Center

Poster #5H  Monday, June 07,   1:00 PM – 5:00 PM    S Hall A2

• Sorafenib (SOR) safety profile in >4600 patients (pts) with renal cell carcinoma (RCC): assessment at 3-month (mo) intervals using an integrated database of 8 company-sponsored studies

Steve K. Gruschkus, PhD; Clara Chen; Michael T. Forsyth: US Oncology

Poster #20C  Saturday,  June 05     2:00 PM – 6:00 PM     S Hall A2

• First line patterns of care and outcomes of HER2 (+) breast cancer patients who progressed after receiving adjuvant trastuzumab in the outpatient community setting.

J. Russell Hoverman, MD, Texas Oncology

Steve K. Gruschkus, PhD; Michael T. Forsyth; Clara Chen: US Oncology

Poster #35D  Monday, June 07,     1:00 PM – 5:00 PM     S Hall A2

• Impact of comorbidities on clinical and economic outcomes among patients with advanced non-small cell lung cancer (NSCLC) receiving care in the community-based outpatient setting.

Mary Ann K. Allison, MD, Comprehensive Cancer Centers of Nevada

Poster #14D  Monday, June 07,   8:00 AM – 12:00 PM    S Hall A2

• Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer.

Allen L. Cohn, MD, Rocky Mountain Cancer Centers

Poster #8F  Saturday,  June 05    2:00 PM – 6:00 PM    S Hall A2

• Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS).

Joyce O'Shaughnessy, MD, Texas Oncology - Baylor Sammons Cancer Center

Jessica D. Jensen; Lina Asmar, PhD: US Oncology Research

Poster #24A  Saturday, June 05,   2:00 PM – 6:00 PM    S Hall A2

• Candidate predictive biomarkers of cetuximab benefit in triple-negative breast cancer

Allen L. Cohn, MD, Rocky Mountain Cancer Centers

Poster #8G  Saturday, June 05    2:00 PM – 6:00 PM   S Hall A2

• Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP).

Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer Center

Poster #4E  Monday, June 07,    1:00 PM – 5:00 PM    S Hall A2

• TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase 3 trial of sunitinib vs. interferon-alfa (IFN-a)

Nicholas Robert, MD, Fairfax-Northern Virginia Hematology-Oncology

Poster #17H  Saturday, June 05,     2:00 PM – 6:00 PM     S Hall A2

• Efficacy of capecitabine (C)-based therapy in patients with first-line metastatic breast cancer (MBC) previously treated with adjuvant anthracyclines and taxanes.

Daniel Von Hoff, MD, FACP, US Oncology Research and Translational Genomics Research Institute (TGen)

Poster #1C  Monday, June 07,    8:00 AM – 12:00 PM    S Hall A2

• A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors.

Guru Sonpavde, MD, Texas Oncology - Deke Slayton Cancer Center

Poster #2C  Monday, June 07,   8:00 AM – 12:00 PM   S Hall A2

• Correlation of disease-free survival at 2 to 3 years and 5-year overall survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy.

Daniel Von Hoff, MD,  FACP, US Oncology Research and Translational Genomics Research Institute (TGen)

Poster #5F  Monday, June 07,    8:00 AM – 12:00 PM   S Hall A2

• Final results from a phase I study of oral TRC102 (methoxyamine HCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexed in patients with refractory cancer.

Daniel Von Hoff, MD, FACP, US Oncology Research and Translational Genomics Research Institute (TGen)

Poster #16D  Monday, June 07,    8:00 AM – 12:00 PM    S Hall A2

• Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1a.

Daniel Von Hoff, MD, FACP, US Oncology Research and Translational Genomics Research Institute (TGen)

Poster #25F  Monday, June 07,   1:00 PM – 5:00 PM   S Hall A2

• Concomitant medication (CM) use in phase I and II cancer clinical trials(CCT): Effects on trial eligibility and potential interactions with study medications.

Patrick J. Flynn, MD, Minnesota Oncology - Minneapolis

Poster #21A  Saturday, June 05,   8:00 AM – 12:00 PM   S Hall A2

• Phase II study of the histone deacetylase (HDAC) inhibitor belinostat for the treatment of myelodysplastic syndrome (MDS).

Guru Sonpavde, MD, Texas Oncology - Deke Slayton Cancer Center

William R. Berry, MD, Cancer Centers of North Carolina - Raleigh

Poster #9H  Monday, June 07,   1:00 PM – 5:00 PM  S Hall A2

• Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial.

Joyce O'Shaughnessy, MD, Texas Oncology - Baylor Sammons Cancer Center

Poster #21E  Saturday, June 05,   2:00 PM – 6:00 PM  S Hall A2

• Differential gene expression analysis and correlation with outcome in HER2-positive metastatic breast cancer treated with HER2-targeted therapy.

Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer Center

Poster #6C  Monday, June 07,    1:00 PM – 5:00 PM    S Hall A2

• Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC).

Karen L. Tedesco, MD, New York Oncology Hematology - Amsterdam

Joanne L. Blum, MD, PhD, Texas Oncology - Baylor Sammons Cancer Center

Cynthia R. Osborne, MD, Texas Oncology - Baylor Sammons Cancer Center

Frankie Ann Holmes, MD, Texas Oncology - Houston Memorial City

Poster #21G  Saturday, June 05,   2:00 PM – 6:00 PM   S Hall A2

• A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC).

Trials in Progress:

Frankie Ann Holmes, MD, Texas Oncology - Houston Memorial City

Joyce O'Shaughnessy, MD, Texas Oncology - Baylor Sammons Cancer Center

Poster #21F  Monday, June 07,   8:00 AM - 12:00 PM   S Hall A2

• Lapatinib and trastuzumab: Molecular effects and efficacy, separately and combined in breast cancer.

Allen L. Cohn, MD, Rocky Mountain Cancer Centers

Poster #36H  Monday, June 07,   8:00 AM - 12:00 PM    S Hall A2

• SPIRITT: a multi-center, open label, randomized, phase 2 clinical trial evaluating safety and efficacy of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with metastatic colorectal cancer (mCRC) with wild-type KRAS tumors.

Allen L. Cohn, MD, Rocky Mountain Cancer Centers

Poster #41  Monday, June 07,   8:00 AM - 12:00 PM    S Hall A2

• A randomized, placebo-controlled, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer with activating ras mutations.

Joyce O'Shaughnessy, MD, Texas Oncology - Baylor Sammons Cancer Center

Gail Wright, MD, Florida Cancer Institute-New Hope - Hudson

Poster #24F  Monday, June 07,    8:00 AM - 12:00 PM S Hall A2

• Three parallel randomized phase 2 trials of dasatinib plus hormonal therapy (HT) in advanced ER+ breast cancer (ER+ BC)

Publish Only

Sheetal Sheth, PharmD, Innovent Oncology

J. Russell Hoverman, MD, Texas Oncology

Brian Turnwald, US Oncology on behalf of US Oncology Pathways Task Force

• Cytotoxic therapy beyond 2nd-line in non-small cell lung cancer: patterns of care and survival.

Clara Chen; Steve K. Gruschkus, PhD; US Oncology

Nicholas J. Vogelzang, MD, Comprehensive Cancer Centers of Nevada

Thomas E. Hutson, DO, PharmD, Texas Oncology - Baylor Sammons Cancer Center

Michael T. Forsyth; William Lopez: US Oncology

• Observational study evaluating resource utilization among metastatic renal cell carcinoma patients treated with mTOR inhibitors in the outpatient community-based setting.